Artelo Biosciences Inc (ARTL) — Cash Flow-to-Debt Ratio

Latest as of March 2026: -0.20x

Artelo Biosciences Inc (ARTL) has a Cash Flow-to-Debt Ratio of -0.20x as of March 2026, meaning its operating cash flow of $-1.19 Million could theoretically repay 0% of its total liabilities ($5.85 Million) in one year. See financial flexibility index of Artelo Biosciences Inc to measure the company's free cash flow as a share of total liabilities.

CF-to-Debt Ratio

-0.20x
Operating CF / Total Liabilities

Operating Cash Flow

$-1.19 Million
USD

Total Liabilities

$5.85 Million
USD

Data as of

Mar 2026
Most recent filing

Artelo Biosciences Inc Cash Flow-to-Debt Ratio (2015–2025)

Historical debt coverage capacity for Artelo Biosciences Inc across 11 annual periods. For the full cash flow conversion analysis, see ARTL cash flow conversion.

Annual Cash Flow-to-Debt Ratio for Artelo Biosciences Inc (2015–2025)

Year-by-year debt coverage analysis for Artelo Biosciences Inc.

Year CF-to-Debt Ratio Operating CF (USD) Total Liabilities YoY Change
2025 -2.09x $-8.52 Million $4.07 Million ▲ +53.9%
2024 -4.54x $-8.35 Million $1.84 Million ▲ +28.7%
2023 -6.36x $-8.21 Million $1.29 Million ▲ +18.9%
2022 -7.84x $-8.01 Million $1.02 Million ▲ +24.3%
2021 -10.36x $-6.14 Million $593.00K ▼ -19.6%
2020 -8.66x $-4.35 Million $502.18K ▼ -216.7%
2019 -2.73x $-2.79 Million $1.02 Million ▲ +9.7%
2018 -3.03x $-1.61 Million $531.97K ▲ +58.9%
2017 -7.37x $-216.82K $29.44K ▼ -592.8%
2016 -1.06x $-18.49K $17.39K ▲ +86.3%
2015 -7.76x $-13.50K $1.74K
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.